-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Immediate Medicine News
On March 29, 2021, Henlius Fuhong announced that it has reached an exclusive license cooperation with Runxin Bio for the BRAF V600E inhibitor RX208.
BRAF protein is an important upstream regulator in the MAPK/ERK signaling pathway.
The BRAF target product RX208 of this cooperation has a brand-new chemical mother nucleus structure and is clinically intended to be used for the treatment of locally advanced or metastatic solid tumors that are positive for BRAF V600E mutations and are not suitable for surgery.
Note: The original text has been deleted